Reading an Autoantibody Report: The Evidence Behind the Numbers

It is late in the outpatient clinic. A 34-year-old schoolteacher has had aching hands and knees for two months, and she is tired all the time. She bought a health package at a laboratory near her home, and she puts the report on the table: ANA positive, 1:80, speckled pattern. On the next page, a line blot shows a weak band for anti-Ro52. She asks the question everyone asks. “Doctor, do I have lupus?”

This is an illustrative case, not a real patient. We will come back to her as each idea arrives.

By the end of this article you will know what each number on that report can tell you, and what it cannot. You will also know why two tools on the MEDiscuss clinical decision support system (CDSS) read such a report the way they do. Their Evidence tabs used to carry all of this. It now lives here, so that the tools stay quick to use at the bedside. If you want the step-by-step approach to a patient with suspected autoimmune disease, read Diagnosing Autoimmune Disease first. This article is the evidence underneath it.

1. Before the test: how likely was the disease?

Start with one idea, because everything else stands on it. Pre-test probability is the probability that the patient has the disease before the result is known. It decides what a positive result means, and nothing about the assay changes it.

Why does it matter so much? Because many healthy people carry autoantibodies. In the United States NHANES survey, antinuclear antibodies were present in 13.8 per cent of the population aged 12 and over (Satoh 2012). That figure is at a 1:80 cut-off, and it is not spread evenly. It was 17.8 per cent of women against 9.6 per cent of men, and it rose with age, with the female-to-male ratio peaking at 40 to 49 years. The same titre in a 60-year-old woman and in a 20-year-old man is not the same finding.

Let us do the arithmetic once, slowly. Take a clinic where 1,000 people are tested and 20 of them have lupus. At a sensitivity of 98 per cent and a specificity of 90 per cent, about 20 of the 20 with lupus test positive and about 98 of the 980 without it also test positive. Of 118 positive results, 20 are true. A positive ANA in that setting is wrong about five times out of six.

“So should I stop ordering the ANA?”

No. Order it with a question attached. Before you send it, ask: what would I do differently if it came back positive, and what would I do differently if it came back negative? If the answer to both is nothing, the test will not help that patient. This question stays in the workup tool, because it changes what you do.

There is an Indian side to this. ANA is increasingly ordered from primary care and in direct-to-consumer laboratory packages, bundled into a panel the patient bought with no clinical question attached. Unpicking an incidental low-titre ANA in a well person now takes up a great deal of rheumatology outpatient time. That is why Stage 1 of the workup tool asks about the patient first: it makes the prior explicit before the number is looked at.

Our schoolteacher is a young woman, so her chance of a positive ANA without disease is higher than a man’s. Before we look at her report again, we need to know whether she has anything else. A rash? Mouth ulcers? Hair loss? Joints that are swollen, not only aching? Protein in the urine, or a low count? Without such findings, her pre-test probability of lupus is low.

2. Sensitivity, specificity and what they mean for one patient

Sensitivity says how often the disease carries the antibody; specificity says how often people without it do not. For an antibody that is found only in a minority of patients but rarely in anyone else, a positive result counts for more than a negative one.

Look at the table with that in mind. A test with high sensitivity and modest specificity is good at ruling a disease out. A test with high specificity is good at ruling it in.

A likelihood ratio joins the two numbers into one. It tells you how much a positive result multiplies the odds of the disease. A ratio of about 4.9 for rheumatoid factor moves the odds a little. A ratio of about 12.5 for anti-CCP moves them a lot. The same result means more in a patient whose illness already looks like the disease. That is why the antibody guide names a pattern and stops: weighing it against the clinical picture is the workup pathway’s job.

3. The titre: how many healthy people are positive?

Across 15 international laboratories, healthy people were ANA-positive at every dilution, with no significant change between 20 and 60 years (Tan 1997). Fifteen international reference laboratories tested sera from healthy individuals on HEp-2 cells at four dilutions (Tan EM, Feltkamp TE, Smolen JS, et al. Arthritis Rheum. 1997;40(9):1601-1611). The figures below are the proportion of healthy people positive at each, and they are the reason a titre is reported at all.

Our patient’s 1:80 puts her among roughly one well person in eight. It lets her in at the door of the 2019 criteria (Aringer 2019). It does not say she has lupus.

4. The pattern: the other half of the test

Titre and pattern are two different results. The titre says how much antibody is present. The pattern says what it is against. A high titre with no pattern reported and no clinical syndrome is a laboratory number; a moderate titre with a centromere pattern in a woman with Raynaud’s is a diagnosis waiting to be confirmed.

The staining pattern on HEp-2 cells, standardised internationally as ICAP anti-cell (AC) codes, predicts which antibodies will be found. A titre reported without a pattern has discarded half of what the test produced (Damoiseaux 2019).

Our patient’s speckled pattern points towards Ro, La, Sm and U1 RNP. That is a reason to look at the specific antibodies, not a diagnosis. Two cautions stay in the tools, because they change the next test. A cytoplasmic pattern can hide behind a report of “ANA negative”. And a negative ANA does not exclude anti-Ro60 or several myositis antibodies.

5. The line blot and the weak band

Most Indian laboratories report the ANA profile, the myositis and systemic sclerosis panels, the liver profile and the neuronal panel as line blots. A strip carries many antigens; a band appears where the patient’s serum binds. A strong band is usually real. A weak band is where line blots go wrong, and the studies show by how much.

• Myositis antibodies are nearly always one per patient (0.2% had more than one) (Betteridge 2019). With higher local cut-offs, multiple positivity in controls fell from 7.2% to 1.1% (Wei 2025). So a strip with three weak myositis bands is more likely to be noise than three diseases.
• TIF1-gamma agrees poorly with immunoprecipitation (kappa 0.21) (Loganathan 2024). A kappa near 0.2 means agreement only a little better than chance.
• Neuronal antigens: 48% of line-blot positives confirmed on tissue, and 8% of line-blot-only patients had a paraneoplastic syndrome (Ruiz-García 2020). Weak SOX1 bands confirmed in 23%, strong in 87% (Arnaldos-Pérez 2023).

“Then why do laboratories report weak bands at all?” Because a weak band is sometimes true, and the laboratory cannot know your patient. You can. Read the strength of the band, and confirm a weak one by a second method before it changes a diagnosis.

Our patient’s weak anti-Ro52 band needs that care twice over. Anti-Ro52 is frequently misreported as a Sjögren’s marker, and on its own it is not one. A weak band of it, in a woman with aching joints and nothing else, does not make a diagnosis.

6. Antibodies that mean a cancer search

A few antibodies change what you do next in a different way: they send you looking for a tumour. The antibody guide prints this on the result card of each one entered. The figures, side by side:

Notice the spread. Hu, Yo and SOX1 almost always mean a cancer. GAD65 rarely does. The same word, “paraneoplastic”, covers both ends.

7. Infections that produce autoantibodies in India

Several antibodies on these tools turn up in infections common here. The rule that stays in the tool is short: look for the infection before the autoimmune disease is named, and before immunosuppression. The evidence behind it:

• Tuberculosis: anti-CCP in 39.6% of pulmonary TB in Prayagraj (Yadav 2020); ANCA in 44% of one series (Flores-Suárez 2003) and 10% of another (Teixeira 2005).
• Leprosy: lupus anticoagulant in 68.6%, mostly IgM antiphospholipid antibodies, with no thrombosis (de Larrañaga 2000).
• Hepatitis C: RF in 40 to 76% (Ingegnoli 2013); anti-LKM-1 in 5 to 10% (EASL 2015).
• HIV: anticardiolipin in about half, rarely beta2GPI-dependent (Sène 2008).
• Infective endocarditis: ANCA in 18%, PR3 or MPO in 8% (Mahr 2014).

Why does this matter so much? Because the treatment for autoimmune disease is immunosuppression, and immunosuppression given to a patient with tuberculosis or endocarditis is harm. Our patient lives in India, where chikungunya arthritis can persist for months and is regularly mistaken for early rheumatoid arthritis. Ask about fever before the joint pains began.

8. What Indian cohorts show

Most of the figures above come from European, American and Chinese patients. Indian data are fewer, and they do not always agree:

• SLE at diagnosis (2,503 patients, conference abstract): anti-dsDNA 70.2%, U1-RNP 52.0%, Ro60 42.1%, Sm 32.2%, La 12.3% (INSPIRE 2025).
• Systemic sclerosis: anti-Scl-70 49.0% and anti-centromere 17.8% in the national registry, the reverse of many European cohorts (Philip 2024).
• Anti-HMGCR myopathy in Indian series occurred without statin exposure (Khoo 2023).
• Anti-PLA2R in 75% of primary membranous nephropathy in Chennai, none of secondary (Gopalakrishnan 2016).

So when a figure from a European cohort says anti-centromere is the commoner antibody of systemic sclerosis, remember that it describes a different population. In the Indian registry, anti-Scl-70 came first.

9. Classification criteria are not diagnostic criteria

Criteria sets such as the 2019 lupus criteria give points and a threshold. It is tempting to treat the threshold as the line between disease and health. It is not. They exist to assemble homogeneous groups for research, and are weighted towards specificity so that trial cohorts are clean.

The commonest misuse is the reverse of the one people expect: not that criteria are used too loosely, but that a patient who genuinely has the disease is denied treatment because a score came to 8 rather than 10. The authors of the 2019 criteria warn against exactly this (Aringer 2019), and the workup tool keeps their warning on screen.

10. Likelihood ratios, and why the workup tool will not multiply them

Post-test odds equal pre-test odds multiplied by the likelihood ratio, but sequential multiplication is only valid when the tests are conditionally independent given the disease state. Autoantibodies are not: a patient with anti-Sm is far more likely than chance to also have anti-dsDNA and a high-titre ANA, and multiplying the ratios treats correlated evidence as independent.

“In plain words?” If two tests tend to come positive together, the second one tells you little that the first did not. Multiplying both ratios counts the same evidence twice, and the probability comes out far too high. So the workup tool does three things:

• It applies the single strongest likelihood ratio present, names it, and states its source and its limitations on screen.
• The one composite figure it uses, the likelihood ratio attached to the number of positive autoantibodies, was measured as a composite in the source study and is legitimate as a single step.
• Where it shows a probability, it repeats the caveat about where the figures come from.

Where do they come from? The likelihood ratios come from Li and colleagues, a retrospective study of 1,297 patients at a single Chinese tertiary hospital, of whom 148 had SLE (Li 2022). The comparison group is other patients who had the panel sent, not healthy people, so these figures describe a rheumatology referral population. Li graded the ANA as immunofluorescence intensity, 1+ to 4+, not as a dilution titre; the titre bands the tool uses are an approximate alignment, which is one more reason to read the output as an order of magnitude. They should not be applied to unselected screening, and no equivalent Indian dataset was available.

Back to the schoolteacher

Put it together. She is a young woman, and her pre-test probability is low unless the examination finds more. One well person in eight carries an ANA at 1:80. Her speckled pattern suggests which antibodies to look for, and her weak anti-Ro52 band does not stand alone. Nothing on her report says lupus. Examine her joints, her skin and her mouth. Check her urine and her blood count, and ask about fever before the pain. If all of that is normal, the kindest thing you can tell her is the truth: many healthy people carry this antibody, and it is not a diagnosis.

If the examination finds swollen joints or a rash, the picture changes, and so does the meaning of the same report. That is pre-test probability at work.

Try this

A 55-year-old man is admitted with weakness of the shoulders and thighs, a rash over his knuckles, and a creatine kinase in the thousands. His myositis line blot shows a strong band for TIF1-gamma. What does this antibody oblige you to do, and over what period? Illustrative case.

Answer. Search for a cancer. In adult dermatomyositis with TIF1-gamma, 41% pooled had a cancer (Best 2019), and the search covers any tumour, within three years of onset (IMACS 2023). The band is strong, so the poor agreement of weak TIF1-gamma bands does not apply here. The antibody guide prints the same search on the result card for TIF1-gamma.

Take-home points

• Decide how likely the disease is before you read the antibody. The same result means different things in different patients.
• An ANA at 1:80 is found in roughly one well person in eight. It is the entry to the lupus criteria, not evidence of lupus.
• Read the pattern as well as the titre, and read the strength of a band on a line blot. Confirm a weak band before it changes a diagnosis.
• In India, look for tuberculosis, leprosy, the viral arthritides, HIV, hepatitis C and endocarditis before naming an autoimmune disease or starting immunosuppression.
• Classification criteria are for research cohorts. A score below the threshold does not mean the patient does not need treatment.

Declaration: the author built and maintains both tools. They are free to use. The figures in this article are those the tools carried in their Evidence tabs on 3 November 2026, each from the source named beside it.

References

1. Satoh M, Chan EKL, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319-2327.
2. Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data. Arthritis Care Res (Hoboken). 2018;70(3):428-438.
3. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev. 2012;12(2):97-106.
4. Braschi E, Shojania K, Allan GM. Anti-CCP: a truly helpful rheumatoid arthritis test? Can Fam Physician. 2016;62(3):234.
5. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808.
6. Walker BS, Peterson LK, Koening C, White SK, Schmidt RL, Tebo AE. Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(6):103100.
7. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40(9):1601-1611.
8. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412.
9. Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48-55.
10. Wei X, Yun J, He J, Sturgess A. Cut-off matters in the interpretation of myositis antibodies by line immunoassay. Rheumatology (Oxford). 2025;64(7):4364-4370.
11. Loganathan A, Gupta L, Rudge A, Lu H, Bowler E, McMorrow F, et al. Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort. Rheumatology (Oxford). 2024;63(9):2363-2371.
12. Ruiz-García R, Martínez-Hernández E, Saiz A, Dalmau J, Graus F. The diagnostic value of onconeural antibodies depends on how they are tested. Front Immunol. 2020;11:1482.
13. Arnaldos-Pérez C, Vilaseca A, Naranjo L, Sabater L, Dalmau J, Ruiz-García R, et al. Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies. Front Immunol. 2023;14:1173484.
14. Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D. Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99(3):256-262.
15. Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P, et al. International guideline for idiopathic inflammatory myopathy-associated cancer screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023;19(12):805-817.
16. Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(11):1771-1776.
17. Lazzaroni MG, Cavazzana I, Colombo E, Dobrota R, Hernandez J, Hesselstrand R, et al. Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR Scleroderma Trials and Research cohort and possible recommendations for screening. J Rheumatol. 2017;44(5):639-647.
18. Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JG, Desestret V, Dubey D, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014.
19. Yadav RK, Raj K, Kachnar V, Mathur MK, Shukla AD. Anti-cyclic citrullinated peptide antibodies in tuberculosis and human immunodeficiency virus. Int J Adv Med. 2020;7(5):804-808.
20. Flores-Suárez LF, Cabiedes J, Villa AR, van der Woude FJ, Alcocer-Varela J. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology (Oxford). 2003;42(2):223-229.
21. Teixeira L, Mahr A, Jaureguy F, Noël LH, Nunes H, Lefort A, et al. Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis. Rheumatology (Oxford). 2005;44(2):247-250.
22. de Larrañaga GF, Forastiero RR, Martinuzzo ME, Carreras LO, Tsariktsian G, Sturno MM, et al. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9(8):594-600.
23. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35(6):727-734.
24. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971-1004.
25. Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008;7(4):272-277.
26. Mahr A, Batteux F, Tubiana S, Goulvestre C, Wolff M, Papo T, et al. Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol. 2014;66(6):1672-1677.
27. Aggarwal A, Chaterjee R, Gupta R, Shobha V, Rajasekhar L, Mathew A, et al. Autoantibodies in a multiinstitutional Indian inception cohort (INSPIRE): prevalence, cluster analysis and phenotype association [abstract PV189a]. J Rheumatol. 2025;52(Suppl 1):196.
28. Philip SS, Janardana R, Shenoy P, Kavadichanda C, Bairwa D, Sircar G, et al. Exploratory clinical subgroup clustering in systemic sclerosis: results from the Indian Progressive Systemic Sclerosis Registry. J Scleroderma Relat Disord. 2024;9(1):29-37.
29. Khoo T, Chinoy H. Anti-HMGCR immune-mediated necrotising myopathy: addressing the remaining issues. Autoimmun Rev. 2023;22(12):103468.
30. Gopalakrishnan N, Abeesh P, Dineshkumar T, Murugananth S, Sakthirajan R, Raman GS, et al. Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: a single center experience. Indian J Nephrol. 2016;26(4):257-261.
31. Li H, Zheng Y, Chen L, Lin S. High titers of antinuclear antibody and the presence of multiple autoantibodies are highly suggestive of systemic lupus erythematosus. Sci Rep. 2022;12(1):1687.
32. Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-889.